Literature DB >> 12242518

Towards a new understanding and classification of chondrogenic neoplasias of the skeleton--biochemistry and cell biology of chondrosarcoma and its variants.

T Aigner1.   

Abstract

Despite substantial knowledge on the clinicopathology of chondrogenic skeletal neoplasms, only limited insights into the biology of the different tumor variants are available. There are virtually no established molecular markers for identification and classification of these neoplasms. In this paper, we present a systematic review of the biochemistry and cell biology of chondrogenic neoplasms of the bone focussing on our own recent investigations. The hallmark of all differentiated chondrogenic tumors is the presence of neoplastic chondrocytic cells responsible for the formation of the characteristic cartilaginous tumor matrix. These cells can show the full differentiation potential of physiologic chondrocytes depending on the tumor entity investigated. The high phenotypic diversity of physiologic chondrocytes explains the previously poorly understood, striking heterogeneity of the neoplastic cells and their surrounding extracellular matrix not only between different but also within chondrogenic tumors. In our studies, tumor classifications, so far based only on histomorphological criteria, were either confirmed or corrected: mesenchymal chondrosarcomas represent the prototypic neoplasm of pre-chondrogenic undifferentiated cells undergoing multifocal chondrocytic differentiation. Enchondromas, osteochondromas, and conventional chondrosarcomas are neoplasms of multi-phenotypically differentiated chondrocytes. Clear cell chondrosarcomas appear to be neoplasms of hypertrophic chondrocytic cells. A peculiar biology is displayed by dedifferentiated chondrosarcomas, which at least in most cases show neither "anaplasia" nor "dedifferentiation", but most likely "transdifferentiation" of part of the neoplastic cells to a cellular phenotype of a different mesenchymal differentiation lineage. Chondroblastomas do not show any chondroblastic differentiation at all. Our studies delineate molecular markers of chondrogenic neoplasms of the skeleton, which have the potential to be the basis of a new biology-orientated classification of skeletal neoplasms. The expression analysis of extracellular matrix genes, in particular of the collagen types, might be able to play herein a leading role in classification and diagnosis, similar to the cytokeratin subtypes or the CDs (cluster of differentiation) for the classification and diagnosis of neoplasms of the epithelia and the lymphatics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12242518     DOI: 10.1007/s00428-002-0641-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

1.  An orderly retreat: Dedifferentiation is a regulated process.

Authors:  Mariko Katoh; Chad Shaw; Qikai Xu; Nancy Van Driessche; Takahiro Morio; Hidekazu Kuwayama; Shinji Obara; Hideko Urushihara; Yoshimasa Tanaka; Gad Shaulsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-21       Impact factor: 11.205

2.  Gene expression dynamics in deer antler: mesenchymal differentiation toward chondrogenesis.

Authors:  István Gyurján; Andrea Molnár; Adrienn Borsy; Viktor Stéger; László Hackler; Zoltán Zomborszky; Péter Papp; Erno Duda; Ferenc Deák; Péter Lakatos; László G Puskás; László Orosz
Journal:  Mol Genet Genomics       Date:  2006-12-05       Impact factor: 3.291

3.  Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.

Authors:  Caroline Peyrode; Valérie Weber; Emmanuelle David; Aurélien Vidal; Philippe Auzeloux; Yves Communal; Marie Mélanie Dauplat; Sophie Besse; François Gouin; Dominique Heymann; Jean Michel Chezal; François Rédini; Elisabeth Miot-Noirault
Journal:  Invest New Drugs       Date:  2011-04-16       Impact factor: 3.850

Review 4.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

5.  Can MR imaging challenge the commonly accepted theory of the pathogenesis of solitary enchondroma of long bone?

Authors:  H Douis; A M Davies; S L James; L G Kindblom; R J Grimer; K J Johnson
Journal:  Skeletal Radiol       Date:  2012-03-17       Impact factor: 2.199

Review 6.  The imaging of cartilaginous bone tumours. II. Chondrosarcoma.

Authors:  H Douis; A Saifuddin
Journal:  Skeletal Radiol       Date:  2012-10-04       Impact factor: 2.199

7.  Dynamic Glycosylation Governs the Vertebrate COPII Protein Trafficking Pathway.

Authors:  Nathan J Cox; Gokhan Unlu; Brittany J Bisnett; Thomas R Meister; Brett M Condon; Peter M Luo; Timothy J Smith; Michael Hanna; Abhishek Chhetri; Erik J Soderblom; Anjon Audhya; Ela W Knapik; Michael Boyce
Journal:  Biochemistry       Date:  2017-12-15       Impact factor: 3.162

8.  In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions.

Authors:  Camille Delaunay-Lemarie; Jean-Baptiste Vincourt; Béatrice Marie; Shyue-Fang Battaglia-Hsu; Stéphanie Etienne; François Sirveaux; Phi Linh Nguyen Thi; Jacques Magdalou; Jean-Michel Vignaud; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2015-06-23       Impact factor: 4.064

9.  p38 MAP kinase signalling is required for hypertrophic chondrocyte differentiation.

Authors:  Lee-Anne Stanton; Shalev Sabari; Arthur V Sampaio; T Michael Underhill; Frank Beier
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

10.  Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity.

Authors:  Christopher A Hamm; Hehuang Xie; Fabricio F Costa; Elio F Vanin; Elisabeth A Seftor; Simone T Sredni; Jared Bischof; Deli Wang; Maria F Bonaldo; Mary J C Hendrix; Marcelo B Soares
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.